Medically reviewed by Prof. Shimon Slavin, MD. Updated: August 2026
What Is Cytokine-Mediated Immunotherapy?
Cytokine-Mediated Immunotherapy (CMI) is a form of cancer immunotherapy aimed at activating and supporting the patient’s own anti-tumor immune response.
Cytokines are signaling proteins that regulate the activity of the immune system. They are involved in immune cell activation, proliferation, and coordination of the immune response against cancer.
At Biotherapy International, the CMI program may include a combination of pegylated interferon alfa-2a and Interleukin-2 (IL-2). Treatment is prescribed individually, taking into account the diagnosis, previous therapies, the patient’s general condition, and treatment tolerance.
How Does Cytokine Therapy Work?
CMI combines two complementary mechanisms of immune stimulation.
Interferon alfa influences immune signaling, supports activation of the immune response, and may enhance the immune system’s ability to recognize tumor cells.
Interleukin-2 (IL-2) is involved in the activation and proliferation of immune cells, particularly T lymphocytes and natural killer (NK) cells.
The aim of this approach is to support anti-tumor immune activity while adjusting treatment intensity to the individual patient’s tolerance.
CMI as Part of an Individualized Immunotherapy Program
At Biotherapy International, CMI is generally used as part of a sequential immunotherapy program.
In particular, following treatment with oncolytic viruses, the next stage may include Cytokine-Mediated Immunotherapy (CMI) or immune checkpoint inhibitors. The choice depends on the type of cancer, response to previous treatment, the patient’s general condition, treatment tolerance, and other clinical factors.
CMI may be considered, in particular, when:
- checkpoint inhibitors are not considered appropriate, are contraindicated, or cannot be used because of unacceptable side effects;
- checkpoint inhibitor therapy has not produced the expected treatment effect;
- a simpler outpatient treatment format is preferred.
Outpatient Immunotherapy
One practical advantage of Cytokine-Mediated Immunotherapy is that, in selected patients, a substantial part of the treatment can be organized on an outpatient basis.
The medications used in Biotherapy’s CMI program are administered by subcutaneous injection. Once treatment has been established and is well tolerated, some injections may be performed outside the clinic in accordance with the physician’s instructions.
The specific medications, treatment schedule, and duration are determined individually.
CMI and Immune Checkpoint Inhibitors
Cytokine therapy and immune checkpoint inhibitors both aim to enhance the anti-tumor immune response, but they work through different mechanisms.
Checkpoint inhibitors, including therapies targeting PD-1, PD-L1, and CTLA-4, block signals that suppress immune activity.
Cytokine-Mediated Immunotherapy works differently. It uses immune signaling molecules to directly stimulate and support the activity of immune cells.
Scientific Background
Cytokine immunotherapy using interferon and Interleukin-2 has been studied in oncology for several decades.
Professor Shimon Slavin and his colleagues participated in clinical research on Cytokine-Mediated Immunotherapy. One published clinical study of Cytokine-Mediated Immunotherapy evaluated outpatient CMI using interferon alfa-2a and Interleukin-2 administered by subcutaneous injection.
Subsequent studies also investigated combinations of IL-2 and interferon as part of cytokine-based immunotherapy.
These studies form part of the scientific basis for the CMI concept. However, current Biotherapy treatment programs are not direct reproductions of historical research protocols. Treatment is individualized according to the patient’s diagnosis, previous therapies, and current clinical condition.
FAQ
